Pediatr. praxi. 2010;11(5):306-311

The present of registered HPV vaccines

doc.MUDr.Roman Chlíbek, Ph.D., MUDr.Jan Smetana, MUDr.Vanda Boštíková

Katedra epidemiologie, Fakulta vojenského zdravotnictví Univerzity obrany, Hradec Králové

Currently there are two available vaccines against human papilloma virus (HPV). Bivalent vaccine Cervarix and quadrivalent vaccine Gardasil.

Both vaccines despite the fact that they are produce by the identical recombinant technology differentiate in a number indicator.

They differ in the number and amount of antigen in the production system used for the preparation of antigens, the adjuvant system

and indication range. The uniqueness of the two vaccines is that they are the first truly anti-cancer vaccines, which have expanded the

possibilities of prevention by vaccination. Another uniqueness of HPV vaccines is significantly higher immune response to vaccination

rather than natural HPV infection. Given that the most important role in HPV protection played virus neutralisation antibodies in serum,

immunogenicity of the vaccine, high IgG antibodies production and duration of vaccine-induced protection of a key for the high efficacy

of HPV vaccination. There are the first head-to-head data comparing the two vaccines in immunogenicity, efficacy and safety. But many

questions remain in the duration of protection, in the minimal titres of protective antibody, the need for booster doses, the effect of

natural HPV infection on the production of antibodies and anamnestic role of memory B cells. The significance of HPV vaccination is to

prevent the most common and most serious diseases associated with HPV infection – cervix carcinoma.

Keywords: safety, cervical cancer, HPV, immunogenicity

Published: October 15, 2010  Show citation